A mass tort lawsuit is a legal action in which multiple individuals file separate claims for damages based on the same defective product, harmful substance, or wrongful conduct. Unlike class actions, where plaintiffs are consolidated into a single group represented collectively, each person in a mass tort retains their own individual claim and maintains greater control over their case. This fundamental distinction means that while mass torts involve many people harmed by the same source, each plaintiff’s claim remains distinct, with its own evidence, damages calculation, and potential settlement or verdict amount.
Mass torts have become one of the most significant areas of civil litigation in the United States. As of September 2025, there are 197,000 pending cases in multi-district litigations (MDLs)—the primary mechanism through which mass torts are coordinated—with a total of 725,000 cases filed across all MDL proceedings. These cases now represent over 70% of the federal civil caseload, making them a dominant force in the American legal system. A clear example is the talcum powder litigation against Johnson & Johnson, which has grown to encompass 66,910 pending cases from individuals alleging that exposure to talc-based products caused mesothelioma and ovarian cancer.
Table of Contents
- How Do Mass Tort Lawsuits Work and What Makes Them Different?
- Mass Torts Versus Class Actions—Critical Legal Differences
- Major Mass Tort Cases and Recent Landmark Settlements
- The Mass Tort Timeline and Litigation Process
- Risks, Limitations, and Warnings in Mass Tort Claims
- Who Files Mass Tort Claims and Current Trends
- The Future of Mass Tort Litigation and Evolving Legal Landscape
- Conclusion
How Do Mass Tort Lawsuits Work and What Makes Them Different?
Mass tort cases typically originate when a defective product, pharmaceutical drug, medical device, or harmful environmental exposure affects hundreds or thousands of people across different jurisdictions. Unlike traditional individual lawsuits where each plaintiff hires their own attorney and files in their home court, mass torts are usually consolidated into a multi-district litigation (MDL) to streamline case management. As of January 2, 2025, there are 170 active MDL dockets in the U.S. federal court system.
Within an MDL, cases from different courts are transferred to a single federal judge who oversees discovery, pretrial motions, and settlement negotiations, while allowing each plaintiff to maintain their individual lawsuit. The key advantage of this structure is efficiency—coordinating thousands of similar cases prevents duplicative discovery and conflicting rulings. However, consolidation also creates pressure toward settlement, as judges and defendants alike recognize that trying thousands of individual cases separately would be economically prohibitive. Each plaintiff in a mass tort can still choose whether to accept a settlement offer negotiated by counsel or proceed to trial if they believe they can achieve a better result. This flexibility distinguishes mass torts from class actions, where individual members are typically bound by the class’s settlement or judgment once it is approved by the court.
Mass Torts Versus Class Actions—Critical Legal Differences
While mass torts and class actions are sometimes confused, they operate under fundamentally different legal principles. In a class action, plaintiffs are grouped together as a single entity, and one or more class representatives bring suit on behalf of the entire group. All class members are bound by the settlement or judgment, even those who did not actively participate in the litigation. Class actions are particularly suited for cases involving small individual damages but widespread harm—such as a price-fixing conspiracy that overcharged millions of consumers by a few dollars each.
Mass torts, by contrast, are better suited for cases involving significant individual damages. Each plaintiff retains control over their claim, their evidence, and their decision to settle or litigate. This means that two individuals harmed by the same defective medical device can negotiate different settlement amounts depending on the severity of their injuries, their medical expenses, and other case-specific factors. In 2024, over 10 individual mass tort settlements surpassed the $1 billion threshold, with the 3M Combat Arms Earplugs litigation resulting in a $6.01 billion settlement for approximately 260,000 service members alleging hearing damage. This settlement amount demonstrates how mass torts can deliver substantial compensation when plaintiffs retain individual claim status—in a class action context, the per-plaintiff recovery would be mechanically divided among all class members, potentially limiting individual recovery for severely injured plaintiffs.
Major Mass Tort Cases and Recent Landmark Settlements
The scale of modern mass tort litigation is extraordinary. The talcum powder litigation involving Johnson & Johnson remains one of the largest active mass tort cases, with 66,910 pending cases. In April 2025, Johnson & Johnson abandoned its earlier bankruptcy strategy, signaling a shift toward direct settlement negotiations. The hair relaxer litigation has grown to 10,168 pending lawsuits as of May 2025, with claims primarily alleging that chemical straightening products cause uterine cancer and other serious health conditions. The C.R.
Bard hernia mesh cases represent another massive litigation, with over 24,000 pending claims from patients alleging that defective mesh implants caused internal injuries and infections. Recent settlements demonstrate the financial scale of mass tort resolutions. In March 2024, 3M agreed to pay $10.3 billion to settle claims from public water systems exposed to PFAS (per- and polyfluoroalkyl substances) contamination. The Roundup litigation involving Bayer resulted in approximately 170,000 lawsuits filed, with Bayer settling roughly 100,000 of these claims for $11 billion in total damages. These settlements reflect the reality that defendants often conclude that global resolution—paying substantial sums upfront—is preferable to years of protracted litigation and the risk of large jury verdicts. In 2024 alone, approximately 135 lawsuits produced awards exceeding $10 million, representing a 52% increase over 2023, with median nuclear verdicts reaching approximately $51 million.
The Mass Tort Timeline and Litigation Process
The lifecycle of a mass tort case typically spans five to ten years or longer, beginning with the initial complaint and proceeding through discovery, pretrial settlement negotiations, and either trial or settlement. Once cases are consolidated into an MDL, the federal judge appoints a plaintiffs’ steering committee—typically comprising experienced mass tort attorneys—to represent the collective interests of all plaintiffs. The steering committee negotiates with the defendant’s counsel, proposes settlement structures, and recommends whether individual plaintiffs should accept settlement offers. A critical phase is the discovery process, during which both sides exchange documents, conduct depositions, and gather evidence.
In large MDLs with hundreds of thousands of cases, discovery can be staggered, with representative cases selected to provide depositions and detailed discovery first. This allows attorneys to evaluate the strength of claims and assess damage ranges before negotiating settlement. Many mass torts settle during this phase—the 3M Combat Arms Earplugs case settled after substantial discovery revealed compelling evidence of the manufacturer’s knowledge of defects. However, some cases proceed to bellwether trials, where a small number of representative cases are tried before a jury to test how a broader jury population will respond to the evidence and arguments. Results from bellwether trials often drive settlement negotiations, as they provide real-world data about jury reactions to plaintiff and defendant positions.
Risks, Limitations, and Warnings in Mass Tort Claims
While mass torts offer the potential for significant compensation, they also carry meaningful risks and limitations that plaintiffs should understand. First, there is no guarantee of recovery. A plaintiff’s success depends on proving causation (that the defendant’s product or conduct caused their specific injury), demonstrating damages, and establishing liability. In pharmaceutical cases, for example, proving that a specific drug caused a plaintiff’s illness can be scientifically complex, particularly when the condition could have multiple causes. Many plaintiffs who join mass tort litigation may ultimately receive reduced settlement amounts or no recovery at all if their individual circumstances do not meet the settlement criteria negotiated for their claim category.
Second, the timeline for recovery is lengthy. The average mass tort case takes years to resolve, during which plaintiffs wait for settlement payments or trial verdicts. Plaintiffs with serious, time-sensitive injuries must consider whether they can afford to wait years for compensation. Additionally, attorney fees in mass tort cases are substantial—typically 25% to 40% of the settlement or verdict amount—which means a plaintiff’s net recovery is reduced significantly. Another limitation is that once a settlement is reached, plaintiffs typically release the defendant from all future liability claims, even if new medical evidence later emerges linking the product to additional injuries. The PFAS litigation is instructive: while over 110 million Americans are estimated to have been exposed to PFAS-contaminated water supplies, not all exposures may be captured within existing litigation, and new health effects could emerge after settlements are finalized.
Who Files Mass Tort Claims and Current Trends
Mass tort plaintiffs are diverse—ranging from consumers harmed by defective products to workers exposed to occupational hazards to patients injured by medical devices or medications. The geographic distribution of verdicts and settlements reveals important patterns. In 2024, California, Florida, New York, and Texas produced 50% of nuclear verdicts (73 out of 135), despite representing only one-third of the U.S. population.
This concentration suggests that certain state court systems and juries are more favorable to plaintiffs, which influences settlement negotiations and case strategy. Emerging mass torts indicate where future litigation will likely concentrate. In February 2025, a new MDL was filed alleging that Depo-Provera, a birth control injection, causes meningioma brain tumors. By March 2025, the litigation had doubled in size to 130 total cases, signaling rapid growth typical of newly identified mass tort claims. Similarly, PFAS contamination continues to generate new lawsuits, with over 110 million Americans estimated to have been exposed through drinking water—a fact that suggests the potential for multi-billion-dollar settlements comparable to the 3M water contamination resolution.
The Future of Mass Tort Litigation and Evolving Legal Landscape
The trajectory of mass tort litigation suggests continued growth and evolution. The current caseload of 197,000 pending MDL cases and 170 active dockets indicates that mass torts will remain a dominant feature of the federal civil justice system for the foreseeable future. As new products emerge and scientific understanding of causation improves, new categories of mass tort claims will likely arise. The rapid expansion of PFAS litigation and the recent emergence of Depo-Provera claims demonstrate how quickly mass torts can scale once a credible link between a product and injury is established.
Looking ahead, defendants increasingly recognize the value of proactive settlement strategies. The $42 billion in class action and government enforcement settlements achieved in 2024 demonstrates that large-scale resolution mechanisms continue to be viable and preferred by defendants over protracted litigation. This trend suggests that future mass tort cases may settle more quickly than historical cases, potentially reducing the average timeline for plaintiff recovery. However, the increasing sophistication of litigation has also led to more rigorous causation defenses, meaning that plaintiffs seeking recovery must have stronger medical and scientific evidence than may have been required in earlier mass tort waves.
Conclusion
A mass tort lawsuit is a mechanism for multiple individuals harmed by the same product, substance, or conduct to pursue compensation while retaining individual control over their claims. Unlike class actions, mass torts allow each plaintiff to maintain their own lawsuit, negotiate their own settlement amount, and exercise greater autonomy over key litigation decisions. The scale of modern mass tort litigation—with 197,000 pending cases across 170 MDL dockets—reflects the reality that defective products, harmful pharmaceuticals, and environmental contamination continue to injure thousands of Americans annually.
If you believe you have been injured by a defective product, medication, or harmful exposure, consulting with an experienced mass tort attorney is the essential first step. An attorney can evaluate whether your claim is likely to be part of an existing MDL, assess the potential value of your case based on comparable settlements and verdicts, and advise you on the timeline and process ahead. Mass tort litigation is complex and requires informed decision-making, but for plaintiffs with serious injuries caused by widely distributed products or exposures, mass torts often represent the most effective path to substantial compensation.